MEDtalks

– Utbildning och vetenskaplig dialog

Dermatologi

2:45

Philips Blue Light Control

Professor Matthias Born visar i denna MEDtalk den dev…

<script src="https://fast.wistia.com/embed/medias/vfcnsw6ttq.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.0% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_vfcnsw6ttq videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
11:27

Clinical proof points

Professor Matthias Born visar i denna MEDtalk den klinis…

<script src="https://fast.wistia.com/embed/medias/pomm3zccy4.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.0% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_pomm3zccy4 videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
9:25

Light and research

I denna korta BestPractice MEDtalk följer vi forskare och professo…

<script src="https://fast.wistia.com/embed/medias/chfymbor6k.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.0% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_chfymbor6k videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
Matthias Born MEDtalk Philips Blue Control 6:11

Trends in light treatment

En ny typ av fototerapi som använder sig av blått LED-ljus är ut…

<script src="https://fast.wistia.com/embed/medias/u4vvn8cylo.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.0% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_u4vvn8cylo videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>

Diabetes / Hjärtkärlsjukdomar

3:04

Hypoglykemier och hjärtkärlhändelser modul 3

Otillräckligt behandlad diabetes kan öka risken …

<script src="https://fast.wistia.com/embed/medias/3cgc47e0jk.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_3cgc47e0jk videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/3cgc47e0jk/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
2:56

Hypoglykemier och hjärtkärlhändelser modul 2

Otillräckligt behandlad diabetes kan öka risken …

<script src="https://fast.wistia.com/embed/medias/x211yinka2.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_x211yinka2 videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/x211yinka2/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
5:16

Hypoglykemier och hjärtkärlhändelser modul 1

Otillräckligt behandlad diabetes kan öka risken …

<script src="https://fast.wistia.com/embed/medias/n4tlaknyn4.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_n4tlaknyn4 videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/n4tlaknyn4/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
38:52

Diabetes och kardiovaskulära risker

Det sker en snabb global ökning av diabetes och ned­satt glukosin…

<script src="https://fast.wistia.com/embed/medias/nt0fbiqvnx.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_nt0fbiqvnx videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
16:11

Nya snabbverkande måltidsinsuliner kan förbättra diabetesbehandling

Finns det behov av att använda nya och snabbare måltidsinsuliner?…

<script src="https://fast.wistia.com/embed/medias/4s5hcim84b.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_4s5hcim84b videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
22:05

Behandling efter metformin

I denna MEDtalk får du svar på hur du genom individualiserad beha…

<script src="https://fast.wistia.com/embed/medias/x2yovmpski.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_x2yovmpski videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
31:14

Nyheter - Analoga Basinsuliner

<script src="https://fast.wistia.com/embed/medias/nm6ne40nto.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_nm6ne40nto videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
23:00

Att matcha rätt NOAK till rätt patient

Många patienter är i AK-behandling. H…

<script src="//fast.wistia.com/embed/medias/makfuhufis.jsonp" async></script><script src="//fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_makfuhufis videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
16:00

Nya ESC guidelines med fokus på patienten och livsstilsfaktorer

Livstidsrisk för att utveckla förmaks…

<script src="//fast.wistia.com/embed/medias/5nhpl73d26.jsonp" async></script><script src="//fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_5nhpl73d26 videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
Per Mårin BestPractice 24:02

Behandlingsstrategier vid diabetes typ 2

Olika läkemedels verkningsmekanismer påverkar patogenesen på olika …

<script src="//fast.wistia.com/embed/medias/01kndgh3uo.jsonp" async></script><script src="//fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_01kndgh3uo videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
Anders Tengblad BestPractice 23:25

Hur behandla äldre patienter med typ 2-diabetes

Den äldre patienten har en ökad risk för kardiovaskulära kompli…

<script src="//fast.wistia.com/embed/medias/up6v4zwhzc.jsonp" async></script><script src="//fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_up6v4zwhzc videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
Magnus Löndahl behandlingstrappa vid diabetes typ 2 BestPractice 26:08

Behandlingstrappa vid typ 2-diabetes

Behandlingstrappa vid typ 2-diabetes Diabetes är en av vår tids s…

<script src="//fast.wistia.com/embed/medias/atvg2c7a1m.jsonp" async></script><script src="//fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_atvg2c7a1m videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
Lars Rydén diabetes BestPractice 25:00

Nytt om diabetes och kardiovaskulära risker

Patienter med diabetes har ökad risk för att utveckla och dö av …

<script src="//fast.wistia.com/embed/medias/6wzscpau6e.jsonp" async></script><script src="//fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_6wzscpau6e videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
Lars Rydén diabetes BestPractice 25:00

Diabetes och hjärtkärlsjukdom - ett multifaktoriellt omhändertagande

Patienter med typ 2-diabetes löper en ökad risk att utveckla och …

<script src="//fast.wistia.com/embed/medias/00vcqgbzed.jsonp" async></script><script src="//fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_00vcqgbzed videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>

Hematologi / Onkologi

1:29

Venetoklax och imbrutinib som första linjens behandling vid KLL

Professor Catherine Diefenbach vid NYU Langone Medical Center och Perl…

<script src="https://fast.wistia.com/embed/medias/33dc8213pg.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_33dc8213pg videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/33dc8213pg/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
3:51

Uppseendeväckande resultat om behandling av myelomatos

PÅ ASCO 2018 lades flera intressanta nya data fram om behandling av m…

<script src="https://fast.wistia.com/embed/medias/eghvlbohui.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_eghvlbohui videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/eghvlbohui/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
1:58

Imponerande responsfrekvens vid B-cellslymfom

Behandling av diffust storcelligt B-cellslymfom med CAR-T-cellsprodukt…

<script src="https://fast.wistia.com/embed/medias/3xrkfabqpf.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_3xrkfabqpf videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/3xrkfabqpf/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
6:56

PET- och MDR-negativitet som prognostisk markör vid follikulärt lymfom

Christiane Pott presenterar nya data från GALLIUM-studien som belyser…

<script src="https://fast.wistia.com/embed/medias/17qmz0y6h6.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_17qmz0y6h6 videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/17qmz0y6h6/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
2:58

Lovande resultat för diffust storcelligt B-cellslymfom och follikulärt lymfom

Polatuzumabvedotin är en konjugerad antikropp som riktas mot CD79b+-c…

<script src="https://fast.wistia.com/embed/medias/mb7jkiv0ds.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_mb7jkiv0ds videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/mb7jkiv0ds/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
2:16

Lågdosinterferon alfa kontra hydroxyurea i behandling av Ph-negativa kroniska myeloproliferativa neoplasier

DALIAH-studien är en dansk prövarinitierad klinisk randomiserad fas …

<script src="https://fast.wistia.com/embed/medias/4f2aq0kim5.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_4f2aq0kim5 videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/4f2aq0kim5/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
2:58

Nordisk studie visar att det är möjligt att förbättra kronisk ITP

Waleed Ghanima, överläkare vid Sykehuset Østfold, presenterar i den…

<script src="https://fast.wistia.com/embed/medias/lmzj98t078.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_lmzj98t078 videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/lmzj98t078/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
6:19

Flera intressanta studier om myeloproliferativa sjukdomar

Eivind Galteland vid Rikshospitalet i Oslo tar med sig flera intressan…

<script src="https://fast.wistia.com/embed/medias/wi2eo7wk9d.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_wi2eo7wk9d videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/wi2eo7wk9d/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
1:44

KML – nyheter från EHA

Henrik Hjorth-Hansen, professor och överläkare vidSt Olavs Hospital …

<script src="https://fast.wistia.com/embed/medias/001wjvtrto.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_001wjvtrto videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/001wjvtrto/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
4:40

Hög grad av klinisk respons vid första linjens kombinationsbehandling av KLL

Med kombinationen ibrutinib och obinutuzumab som första linjens behan…

<script src="https://fast.wistia.com/embed/medias/70vpn1li0t.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_70vpn1li0t videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/70vpn1li0t/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
2:16

Säkerhetsdata för kombinationsbehandling av AL-amyoloidos

AL-amyloidos är den vanligaste undergruppen av amyoloidos. Avlagringa…

<script src="https://fast.wistia.com/embed/medias/57ux7vp3lq.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_57ux7vp3lq videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/57ux7vp3lq/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
4:37

Signifikant ökad PFS vid behandling av myelomatos

I fas III-studien OPTIMISMM jämförs 559 patienter med myelomatos som…

<script src="https://fast.wistia.com/embed/medias/srdbhz8tm1.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_srdbhz8tm1 videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/srdbhz8tm1/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
4:46

MDR-negativitet uppnås av 82 procent vid första linjens behandling av KLL

Ibrutinib är en tyrosinkinashämmare som hämmar signalmolekylen BTK….

<script src="https://fast.wistia.com/embed/medias/pkio9zi3uz.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_pkio9zi3uz videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/pkio9zi3uz/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
2:17

Ny effektiv frontline-behandling av KLL

Yngre personer med KLL kan komma att erbjudas en ny effektiv behandlin…

<script src="https://fast.wistia.com/embed/medias/xjtdj8poco.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_xjtdj8poco videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/xjtdj8poco/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
6:02

Trippelbehandling av högriskpatienter med myelomatos

Carfilzomib, cyklofosfamid och dexametason är en effektiv och generel…

<script src="https://fast.wistia.com/embed/medias/abrvkav943.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_abrvkav943 videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/abrvkav943/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
3:12

Rutinmässig användning av djup sekvensering vid KML

Resultaten från den första prospektiva studien av rutinmässig anvä…

<script src="https://fast.wistia.com/embed/medias/di8h13na0l.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_di8h13na0l videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/di8h13na0l/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
4:54

Bättre behandling av köldagglutininsjukdom

Resultaten från en nordisk studie som presenterades vid EHA visar att…

<script src="https://fast.wistia.com/embed/medias/h8i06fo6sd.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_h8i06fo6sd videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/h8i06fo6sd/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
3:15

Sekvensering av behandling vid KLL

Även om ett stort antal studier av KLL-behandling redan pågår är d…

<script src="https://fast.wistia.com/embed/medias/l3wn9ckeqd.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_l3wn9ckeqd videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/l3wn9ckeqd/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
2:58

Möjligt att hitta KLL-patienter med risk för immundysfunktion

En del patienter med KLL dör till följd av infektioner. För att red…

<script src="https://fast.wistia.com/embed/medias/xmk0lmxggu.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_xmk0lmxggu videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/xmk0lmxggu/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
2:35

Tidsbegränsad behandling av högriskpatienter med recidiverande KLL

Carsten Utoft Niemann presenterar de första mycket lovande resultaten…

<script src="https://fast.wistia.com/embed/medias/osig3cjt4i.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_osig3cjt4i videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/osig3cjt4i/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
4:02

Bättre överlevnad för patienter med KLL i behandling med Gazyvaro

KLL-patienter med komorbiditet uppnår bättre överlevnad med obinutu…

<script src="https://fast.wistia.com/embed/medias/o9zw52ytrc.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_o9zw52ytrc videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/o9zw52ytrc/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
12:06

Smouldering myeloma and high risk patients - a close look at GEM-CESAR and CENTAURUS studies (1:3)

Watch dr. Fredrik Schjesvold discuss smouldering myeloma and the tw…

<script src="https://fast.wistia.com/embed/medias/xypykci1kt.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_xypykci1kt videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/xypykci1kt/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
12:29

Discussion of established combinations and new combinations in multiple myeloma (2:3)

Watch dr. Fredrik Schjesvold take you through NEW documentation for…

<script src="https://fast.wistia.com/embed/medias/7giy7ui208.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_7giy7ui208 videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/7giy7ui208/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
8:49

Should all eligible patients with multiple myeloma have tandem transplant? (3:3)

Watch dr. Fredrik Schjesvold take you through the documentation in …

<script src="https://fast.wistia.com/embed/medias/fqcwho4tnv.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_fqcwho4tnv videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/fqcwho4tnv/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
4:04

Risken för djup ventrombos och lungemboli vid cancer kan reduceras

Incidensen av venös trombos bland inlagda patienter med aktiv cancer …

<script src="https://fast.wistia.com/embed/medias/ucrne1oatm.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_ucrne1oatm videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
10:13

Uppseendeväckande resultat

Patienter med avancerat Hodgkins lymfom i stadium III eller IV kan med…

<script src="https://fast.wistia.com/embed/medias/d2dmb3v30u.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_d2dmb3v30u videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
4:59

Paradigmskifte för användning av MRD

”Minimal residual disease” (MRD) var fokus vid flera intressanta s…

<script src="https://fast.wistia.com/embed/medias/kb2mzq1r6h.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_kb2mzq1r6h videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
1:48

Utsättning av TKI-behandling vid KML

Varaktigheten av “Deep Molecular Response” är den viktigaste fakt…

<script src="https://fast.wistia.com/embed/medias/kenrt8ujfw.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_kenrt8ujfw videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
4:10

Reglering av behandlingsrespons

Val av första linjens behandling vid myeolomatos, reglering av behand…

<script src="https://fast.wistia.com/embed/medias/eqfnlbv18k.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_eqfnlbv18k videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
3:29

Större sensitivitet för BCL2-hämmare vid KLL

Behandlingen av KLL befinner sig i en ny era med flera nya behandlings…

<script src="https://fast.wistia.com/embed/medias/sry378yzy2.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_sry378yzy2 videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
2:30

Nytt om köldagglutininsyndrom och KLL

Enligt Henrik Hjorth-Hansen kan nu patienter med köldagglutininsyndro…

<script src="https://fast.wistia.com/embed/medias/ghucxeuf9e.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_ghucxeuf9e videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
2:27

Imponerande data om KLL

Nya resultat för behandling av KLL presenterades vid flera sessioner,…

<script src="https://fast.wistia.com/embed/medias/xsubgo1rmg.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_xsubgo1rmg videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
2:08

Fortsatt nivolumab-behandling vid Hodgkins lymfom

Patienter med recidiverande/refraktärt klassiskt Hodgkins lymfom som …

<script src="https://fast.wistia.com/embed/medias/dur7njnr40.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_dur7njnr40 videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
11:55

Hur behandla patienter i återfall efter behandling med ASCT?

Hör professor Philippe Moreau redogöra för två centrala område…

<script src="https://fast.wistia.com/embed/medias/njmpoaszdr.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_njmpoaszdr videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
13:24

Behandlingsalgoritm vid multipelt myelom

Hör professor Philippe Moreau redogöra för två centrala område…

<script src="https://fast.wistia.com/embed/medias/e30ohomwpu.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_e30ohomwpu videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>

ASH 2017

12:06

Smouldering myeloma and high risk patients - a close look at GEM-CESAR and CENTAURUS studies (1:3)

Watch dr. Fredrik Schjesvold discuss smouldering myeloma and the tw…

<script src="https://fast.wistia.com/embed/medias/xypykci1kt.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_xypykci1kt videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/xypykci1kt/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
12:29

Discussion of established combinations and new combinations in multiple myeloma (2:3)

Watch dr. Fredrik Schjesvold take you through NEW documentation for…

<script src="https://fast.wistia.com/embed/medias/7giy7ui208.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_7giy7ui208 videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/7giy7ui208/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
8:49

Should all eligible patients with multiple myeloma have tandem transplant? (3:3)

Watch dr. Fredrik Schjesvold take you through the documentation in …

<script src="https://fast.wistia.com/embed/medias/fqcwho4tnv.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_fqcwho4tnv videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/fqcwho4tnv/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
4:04

Risken för djup ventrombos och lungemboli vid cancer kan reduceras

Incidensen av venös trombos bland inlagda patienter med aktiv cancer …

<script src="https://fast.wistia.com/embed/medias/ucrne1oatm.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_ucrne1oatm videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
10:13

Uppseendeväckande resultat

Patienter med avancerat Hodgkins lymfom i stadium III eller IV kan med…

<script src="https://fast.wistia.com/embed/medias/d2dmb3v30u.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_d2dmb3v30u videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
4:59

Paradigmskifte för användning av MRD

”Minimal residual disease” (MRD) var fokus vid flera intressanta s…

<script src="https://fast.wistia.com/embed/medias/kb2mzq1r6h.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_kb2mzq1r6h videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
1:48

Utsättning av TKI-behandling vid KML

Varaktigheten av “Deep Molecular Response” är den viktigaste fakt…

<script src="https://fast.wistia.com/embed/medias/kenrt8ujfw.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_kenrt8ujfw videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
4:10

Reglering av behandlingsrespons

Val av första linjens behandling vid myeolomatos, reglering av behand…

<script src="https://fast.wistia.com/embed/medias/eqfnlbv18k.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_eqfnlbv18k videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
3:29

Större sensitivitet för BCL2-hämmare vid KLL

Behandlingen av KLL befinner sig i en ny era med flera nya behandlings…

<script src="https://fast.wistia.com/embed/medias/sry378yzy2.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_sry378yzy2 videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
2:30

Nytt om köldagglutininsyndrom och KLL

Enligt Henrik Hjorth-Hansen kan nu patienter med köldagglutininsyndro…

<script src="https://fast.wistia.com/embed/medias/ghucxeuf9e.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_ghucxeuf9e videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
2:27

Imponerande data om KLL

Nya resultat för behandling av KLL presenterades vid flera sessioner,…

<script src="https://fast.wistia.com/embed/medias/xsubgo1rmg.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_xsubgo1rmg videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
2:08

Fortsatt nivolumab-behandling vid Hodgkins lymfom

Patienter med recidiverande/refraktärt klassiskt Hodgkins lymfom som …

<script src="https://fast.wistia.com/embed/medias/dur7njnr40.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_dur7njnr40 videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>

EHA 2018

6:56

PET- och MDR-negativitet som prognostisk markör vid follikulärt lymfom

Christiane Pott presenterar nya data från GALLIUM-studien som belyser…

<script src="https://fast.wistia.com/embed/medias/17qmz0y6h6.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_17qmz0y6h6 videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/17qmz0y6h6/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
2:58

Lovande resultat för diffust storcelligt B-cellslymfom och follikulärt lymfom

Polatuzumabvedotin är en konjugerad antikropp som riktas mot CD79b+-c…

<script src="https://fast.wistia.com/embed/medias/mb7jkiv0ds.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_mb7jkiv0ds videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/mb7jkiv0ds/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
2:16

Lågdosinterferon alfa kontra hydroxyurea i behandling av Ph-negativa kroniska myeloproliferativa neoplasier

DALIAH-studien är en dansk prövarinitierad klinisk randomiserad fas …

<script src="https://fast.wistia.com/embed/medias/4f2aq0kim5.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_4f2aq0kim5 videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/4f2aq0kim5/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
2:58

Nordisk studie visar att det är möjligt att förbättra kronisk ITP

Waleed Ghanima, överläkare vid Sykehuset Østfold, presenterar i den…

<script src="https://fast.wistia.com/embed/medias/lmzj98t078.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_lmzj98t078 videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/lmzj98t078/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
6:19

Flera intressanta studier om myeloproliferativa sjukdomar

Eivind Galteland vid Rikshospitalet i Oslo tar med sig flera intressan…

<script src="https://fast.wistia.com/embed/medias/wi2eo7wk9d.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_wi2eo7wk9d videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/wi2eo7wk9d/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
1:44

KML – nyheter från EHA

Henrik Hjorth-Hansen, professor och överläkare vidSt Olavs Hospital …

<script src="https://fast.wistia.com/embed/medias/001wjvtrto.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_001wjvtrto videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/001wjvtrto/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
4:40

Hög grad av klinisk respons vid första linjens kombinationsbehandling av KLL

Med kombinationen ibrutinib och obinutuzumab som första linjens behan…

<script src="https://fast.wistia.com/embed/medias/70vpn1li0t.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_70vpn1li0t videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/70vpn1li0t/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
2:16

Säkerhetsdata för kombinationsbehandling av AL-amyoloidos

AL-amyloidos är den vanligaste undergruppen av amyoloidos. Avlagringa…

<script src="https://fast.wistia.com/embed/medias/57ux7vp3lq.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_57ux7vp3lq videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/57ux7vp3lq/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
4:37

Signifikant ökad PFS vid behandling av myelomatos

I fas III-studien OPTIMISMM jämförs 559 patienter med myelomatos som…

<script src="https://fast.wistia.com/embed/medias/srdbhz8tm1.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_srdbhz8tm1 videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/srdbhz8tm1/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
4:46

MDR-negativitet uppnås av 82 procent vid första linjens behandling av KLL

Ibrutinib är en tyrosinkinashämmare som hämmar signalmolekylen BTK….

<script src="https://fast.wistia.com/embed/medias/pkio9zi3uz.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_pkio9zi3uz videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/pkio9zi3uz/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
2:17

Ny effektiv frontline-behandling av KLL

Yngre personer med KLL kan komma att erbjudas en ny effektiv behandlin…

<script src="https://fast.wistia.com/embed/medias/xjtdj8poco.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_xjtdj8poco videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/xjtdj8poco/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
6:02

Trippelbehandling av högriskpatienter med myelomatos

Carfilzomib, cyklofosfamid och dexametason är en effektiv och generel…

<script src="https://fast.wistia.com/embed/medias/abrvkav943.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_abrvkav943 videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/abrvkav943/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
3:12

Rutinmässig användning av djup sekvensering vid KML

Resultaten från den första prospektiva studien av rutinmässig anvä…

<script src="https://fast.wistia.com/embed/medias/di8h13na0l.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_di8h13na0l videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/di8h13na0l/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
4:54

Bättre behandling av köldagglutininsjukdom

Resultaten från en nordisk studie som presenterades vid EHA visar att…

<script src="https://fast.wistia.com/embed/medias/h8i06fo6sd.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_h8i06fo6sd videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/h8i06fo6sd/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
3:15

Sekvensering av behandling vid KLL

Även om ett stort antal studier av KLL-behandling redan pågår är d…

<script src="https://fast.wistia.com/embed/medias/l3wn9ckeqd.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_l3wn9ckeqd videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/l3wn9ckeqd/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
2:58

Möjligt att hitta KLL-patienter med risk för immundysfunktion

En del patienter med KLL dör till följd av infektioner. För att red…

<script src="https://fast.wistia.com/embed/medias/xmk0lmxggu.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_xmk0lmxggu videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/xmk0lmxggu/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
2:35

Tidsbegränsad behandling av högriskpatienter med recidiverande KLL

Carsten Utoft Niemann presenterar de första mycket lovande resultaten…

<script src="https://fast.wistia.com/embed/medias/osig3cjt4i.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_osig3cjt4i videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/osig3cjt4i/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
4:02

Bättre överlevnad för patienter med KLL i behandling med Gazyvaro

KLL-patienter med komorbiditet uppnår bättre överlevnad med obinutu…

<script src="https://fast.wistia.com/embed/medias/o9zw52ytrc.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_o9zw52ytrc videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/o9zw52ytrc/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>

Lungmedicin

4:14

Hur ser behandlingstrappan ut vid KOL?

I tre korta MEDtalks ger Christer Janson,

<script src="https://fast.wistia.com/embed/medias/udd4g3z5td.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_udd4g3z5td videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/udd4g3z5td/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
8:38

Hur förebygger man KOL-exacerbationer?

I tre korta MEDtalks ger Christer Janson,

<script src="https://fast.wistia.com/embed/medias/x8rwaymzt8.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_x8rwaymzt8 videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/x8rwaymzt8/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
5:41

Förebyggande behandling mot exacerbationer vid KOL

I tre korta MEDtalks ger Christer Janson,

<script src="https://fast.wistia.com/embed/medias/79hu0sjtd4.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_79hu0sjtd4 videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/79hu0sjtd4/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
8:57

Hur seponera behandling med steroider?

Här får du…

<script src="https://fast.wistia.com/embed/medias/1tegmrxqej.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_1tegmrxqej videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
8:21

Hur behandla KOL i öppenvården?

Vi har många patienter i öppenvården med KOL. Det är av stor kl…

<script src="https://fast.wistia.com/embed/medias/vppfazho2h.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_vppfazho2h videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
6:28

Hur upptäcks KOL-patienten?

<script src="https://fast.wistia.com/embed/medias/tqvmbm9y0c.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_tqvmbm9y0c videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
Kjell Larson MEDtalk 26:40

Differentialdiagnostik

Astma och KOL liknar varandra när det gäller symtom men skillnade…

<script src="https://fast.wistia.com/embed/medias/h9cxmkao4h.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:75.0% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_h9cxmkao4h videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
26:31

Nyheter inom KOL-behandling

Livsstilsändringar utgör en viktig del i behandlin­gen och det k…

<script src="//fast.wistia.com/embed/medias/7qqov4mso0.jsonp" async></script><script src="//fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_7qqov4mso0 videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
Christer Janson KOL BestPractice 20:24

Terapival vid KOL - nya riktlinjer från Läkemedelsverket

Det har kommit nya riktlinjer från Läkemedelsverket för behandli…

<script src="//fast.wistia.com/embed/medias/2j44pt55c2.jsonp" async></script><script src="//fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_2j44pt55c2 videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>

Multipel skleros

13:02

Återställning av immunsystem vid multipel skleros

Behandlingsstrategierna vid multipel skleros har ändrats under de …

<script src="https://fast.wistia.com/embed/medias/o3ecikyfbt.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_o3ecikyfbt videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>

Reumatologi

20:08

Behandling av RA med JAK-hämmare - Kliniska erfarenheter från Australien

I enlighet med de uppdaterade riktlinjerna från EULAR är nu JAK-h…

<script src="https://fast.wistia.com/embed/medias/qrsiprxtks.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_qrsiprxtks videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
21:07

The importance of early diagnosis and new treatment of RA

This Medtalk is a conversation among former EULAR president and Pro…

<script src="https://fast.wistia.com/embed/medias/6mogui3vcv.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_6mogui3vcv videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>